ORIGINAL

Thrombolysis in acute ischemic stroke in centers lacking a stroke unit: Referral to reference center or on-site treatment?☆

J. Latour-Pérez a,*, P. Galdos Anuncibay b

a Servicio de Medicina Intensiva, Hospital General Universitario de Elche, Elche, Alicante, Spain
b Servicio de Medicina Intensiva, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain

Received 4 October 2011; accepted 24 December 2011

Objectives: To assess the clinical impact of on-site thrombolysis vs referral to another hospital in patients with ischemic stroke attended in a hospital lacking a stroke unit.

Design: Expected value decision analysis and Monte Carlo simulation.

Patients and setting: Decision analysis based on a cohort study (SIT-MOST) and a meta-analysis of randomized trials of thrombolysis vs placebo in patients with acute ischemic stroke.

Interventions: On-site thrombolysis (in hospitals lacking a stroke unit) vs delayed thrombolysis in a reference hospital.

Main outcomes: Neurological outcome (modified Rankin scale) three months after admission according to the delay in the introduction of thrombolysis.

Results: At baseline (initial delay of 135 min, travel time 60 min), on-site treatment was more effective than referral to another hospital (number of patients with favorable neurological outcome 45.3% vs 41.3%). In patients seen within 45 min of the onset of symptoms, for every 10 patients transferred there was an additional case with an unfavorable neurological outcome that could have been avoided with on-site thrombolysis. In the Monte Carlo analysis, biased against on-site treatment by a reduction in effectiveness of 30%, on-site treatment was superior to patient referral in 77.2% of the cases.

Conclusions: The available evidence does not support the recommendations of the national stroke strategy or some regional plans that discourage the administration of thrombolysis in hospitals without stroke units.

© 2011 Elsevier España, S.L. and SEMICYUC. All rights reserved.

☆ Please cite this article as: Latour-Pérez J, Galdos Anuncibay P. Trombolisis en el ictus isquémico agudo en centros sin unidad de ictus: ¿derivación a centro de referencia o tratamiento in situ? Med Intensiva. 2012;36:324-8.

* Corresponding author.

E-mail address: jlatour@coma.es (J. Latour-Pérez).
Trombolisis en el ictus isquémico agudo en centros sin unidad de ictus: ¿derivación a centro de referencia o tratamiento in situ?

Resumen
Objetivo: Cuantificar los resultados clínicos de la trombolisis in situ frente a la trombolisis diferida en un hospital de referencia en pacientes con ictus isquémico atendidos en un hospital sin unidad de ictus.

Diseño: Análisis de decisiones de valor esperado y simulación de Monte Carlo.

Pacientes y ámbito: Simulación basada en un estudio de cohortes (SIT-MOST) y un meta-análisis de ensayos aleatorizados de trombolisis contra placebo en pacientes con ictus isquémico agudo.

Intervenciones: Trombolisis in situ frente a la trombolisis diferida en un centro dotado de unidad de ictus.

Variables principales: Resultados neurológicos (escala de Rankin modificada) a los tres meses del ingreso en función de la demora en la aplicación de la trombolisis.

Resultados: En las condiciones basales del estudio SIT-MOST (demora inicial de 135 min, tiempo de transporte de 60 min) el tratamiento in situ fue más efectivo que la derivación a otro hospital (número de pacientes con resultado neurológico favorable de 45,3% frente al 41,3%). En los pacientes atendidos a los 45 minutos, de cada 10 pacientes trasladados se produce un caso adicional con resultado neurológico desfavorable, que se hubiera evitado con el tratamiento trombolítico in situ. En el análisis de Monte Carlo, sesgado en contra del tratamiento in situ mediante una reducción de la efectividad del 30%, el tratamiento in situ fue superior a la derivación de los enfermos en el 77,2% de los casos.

Conclusiones: La evidencia disponible no apoya las recomendaciones de la estrategia nacional del ictus y de los diversos planes autonómicos que desaconsejan la realización de trombolisis en hospitales sin unidades de ictus.

© 2011 Elsevier España, S.L. y SEMICYUC. Todos los derechos reservados.

Introduction

Early thrombolysis in ischemic stroke patients reduces the area of cerebral infarction and improves the functional outcome after three months. The benefit of such treatment decreases on a continuous basis with the time elapsed from symptoms onset; administration therefore should be carried out as soon as possible.

In Spain, different autonomous regions have developed plans for the administration of thrombolysis in ischemic stroke. These strategies often advise thrombolysis in centers lacking a Stroke Unit, and recommend transferring the patient to a reference center. Unfortunately, this recommendation is not based on the best available evidence but on the opinions of experts, which are hampered by potential conflicting professional interests, and fails to take into consideration the added delay in treatment implied by patient transfer.

Quality evidence has recently become available on the efficacy of thrombolysis according to the time from symptoms onset, thereby allowing a rational approach to the problem, from the patient perspective.

The present study involves decision analysis to evaluate the relative effectiveness of transfer to a reference center vs on-site treatment of ischemic stroke in patients amenable to thrombolytic treatment.

Methods

The analysis was based on a decision tree with two alternatives: on-site treatment vs referral to a reference hospital (Fig. 1). The primary clinical outcome (terminal nodes of the decision tree) was the recording of a favorable neurological outcome (defined as a score of 0–1 on the modified Rankin scale) after three months (Table 1).

The association between the efficacy of thrombolytic treatment and the time elapsed from symptoms onset was based on the study published by Lees et al., a metaanalysis of 8 randomized clinical trials estimating the effectiveness (odds ratio) of thrombolysis according to the time to treatment. To this effect, we adjusted a geometric function to the data of the mentioned metaanalysis, based on linearized

![Figure 1](https://via.placeholder.com/150)

**Figure 1** Decision tree. T1: Symptoms-treatment decision time: Triangular (135/45/270). T2: Secondary transfer time: Triangular (60/30/120).

Po: A priori probability of a favorable neurological outcome: Triangular (0.34/0.25/0.45). Px: Penalization due to lack of a Stroke Unit: Triangular (0.3/0.0.5). In the case of on-site treatment, the odds ratio is penalized by the variable Px. In the case of treatment in a reference center, the delay is penalized by the transfer time.
models. The resulting function showed an excellent data fit ($r^2 = 0.9787$): \[
\text{OR} = 12.663687 \times \text{Delay}^{-0.418035}
\]

where OR = odds ratio of a favorable neurological outcome of thrombolytic treatment vs placebo; Delay = minutes from symptoms onset to treatment.

With the purpose of evaluating the possible impact of the lack of a Stroke Unit, the OR in the case of on-site thrombolysis was penalized by a fictitious variable (Px), according to the following expressions:

\[
\ln(\text{OR penalized}) = \ln(12.663687 \times \text{Delay}^{-0.418035}) \times (1 - \text{Px})
\]

\[
\text{OR penalized} = \exp(\ln(\text{OR}))
\]

where \(\ln(\text{OR})\) = Naperian logarithm of OR; Px = penalization due to the lack of a Stroke Unit (a probability ranging from 0 = absence of penalization to 1 = penalization of 100%); \(\exp\) = exponential.

The OR values were transformed into relative risk (RR) values by means of the following expression: \(\frac{\text{OR}}{[1 - \text{Po}] + [\text{Po} \times \text{OR}]}\)

where RR = relative risk (variable according to the time elapsed); \(\text{Po}\) = baseline prevalence of a favorable neurological outcome (without thrombolysis).

The practical meaning of these expressions is shown in Table 2.

The number needed to treat (NNT) was calculated as follows:

\[
\text{NNT} = \frac{1}{\text{DR}}
\]

where NNT = number needed to treat to secure an additional case of favorable neurological outcome after three months; DR = absolute difference of the expected prevalences of favorable neurological outcome between the referral and on-site treatment strategies.

The impact of treatment delay and of penalization due to the lack of a Stroke Unit was assessed by means of sensitivity analysis. To this effect, the expected value of each strategy was recalculated for different values of these variables, checking whether the optimum strategy changed or not.\(^6\) However, traditional sensitivity analysis is not very practical for jointly assessing the effect of more than two variables. As a result, the deterministic sensitivity analysis was completed by a Monte Carlo simulation\(^6,10\) – a probabilistic sensitivity analysis taking into account all the variables subject to uncertainty simultaneously. To this effect, instead of directly including the values of the variables in the decision tree, it is assumed that each variable included in the model has a probability distribution. In our case the variables were: the baseline prevalence of a favorable neurological outcome without thrombolytic treatment, the interval from symptoms onset to treatment, the transfer time to the reference center, and the penalization due to the lack of a Stroke Unit. These variables in turn were transformed into triangular distributions with most frequent/minimum/maximum values of 0.34/0.25/0.45; 135/30/160; 60/45/120; and 0.3/0.0.5, respectively. These four distributions were randomly sampled in 10,000 simulations, registering the number of cases in which each alternative was of choice. The end result offers a compact measure of the uncertainty of the results associated to the probabilistic nature of the input variables.

Results

The baseline scenario assumed a prevalence of favorable neurological outcomes in the control group (i.e., not subjected to thrombolysis) of 34%, an interval from symptoms onset of 135 min (similar to the data of the SIT-MOST

<table>
<thead>
<tr>
<th>Table 1 Modified Rankin classification.</th>
</tr>
</thead>
<tbody>
<tr>
<td>No symptoms</td>
</tr>
<tr>
<td>1 Moderate disability. Unlikely to perform routine activities with little discomfort of activities (e.g., ability to care for personal needs of help)</td>
</tr>
<tr>
<td>3 Spasticity without symptoms</td>
</tr>
<tr>
<td>4 Spasticity with symptoms and discomfort</td>
</tr>
<tr>
<td>5 Severe disability. Unable to perform routine activities and severe discomfort of activities (e.g., needs some help)</td>
</tr>
<tr>
<td>6 Death</td>
</tr>
</tbody>
</table>

Table 2 Relative risk of a favorable outcome with thrombolysis involving different degrees of penalization due to the lack of a Stroke Unit.

<table>
<thead>
<tr>
<th>Penalization</th>
<th>Symptoms onset-treatment time (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45</td>
</tr>
<tr>
<td>0</td>
<td>1.68</td>
</tr>
<tr>
<td>0.30</td>
<td>1.47</td>
</tr>
<tr>
<td>0.50</td>
<td>1.33</td>
</tr>
</tbody>
</table>

The probability of a favorable neurological outcome without thrombolysis is assumed to be 0.34.
Thrombolysis in acute ischemic stroke in centers lacking a stroke unit

Figure 2  Sensitivity analysis of the variable symptoms-treatment decision time. The prevalence of a favorable outcome decreases as the time from symptoms onset to thrombolysis treatment decision increases. In the considered time range, the expected prevalence of favorable outcomes is always greater with the on-site treatment strategy. The difference between the two strategies is greater at the start of the clinical condition, and decreases over time.

In the absence of randomized clinical trials establishing face-to-face comparisons of these two strategies, our study involves a decision analysis based on the best available evidence regarding the impact of a delay in thrombolysis upon the clinical outcome, and biased in favor of patient transfer to a Stroke Unit. According to the results obtained, the treatment of choice in a baseline situation similar to that described in different epidemiological studies is on-site patient treatment. Transfer to another center would only be justified when the effectiveness of on-site thrombolytic treatment is taken to be far less effective than that administered in a hospital with a Stroke Unit.

This latter assumption does not appear reasonable, since it contradicts the evidence derived from observational studies that support the following conclusions: (1) thrombolysis in patients without signs of bleeding in the computed axial tomography study is safe; (2) following a brief training intervention, the clinical results of thrombolysis obtained in centers with physicians not specialized in stroke are comparable to those reported by the published clinical trials; (3) the neurological outcome is not associated to initial care provided by a neurologist; (4) the bleeding complications of thrombolysis increase when the door-to-needle interval exceeds 60 min.

These results would advise urgent modification of some of the Spanish regional plans, authorizing “stroke teams” to administer fibrinolytic agents on-site after establishing a correct indication, guaranteed through adequate training and accreditation of the clinicians and/or remote assistance provided by an expert.

The data obtained also point to the need for the health authorities to be sufficiently flexible to adapt to

Discussion

Many studies show Stroke Units to improve the clinical outcome of ischemic stroke patients compared with conventional treatment in the ward. Unfortunately, however, the number of such Units is limited, and sometimes transfer to the reference center cannot be made in an acceptable period of time. Under such conditions it is necessary to decide between patient transfer to a Stroke Unit (with the associated additional delay) or on-site treatment in any of its variants (admission to Intensive Care, telemedicine-assisted thrombolysis, thrombolysis and referral—“drip and ship” etc.).

study), and an additional delay due to transfer to the reference center of 60 min. Under these conditions, the expected prevalence of favorable neurological outcomes was 45.3% in the on-site treatment group vs 41.3% in the patients transferred to the reference center (number needed to treat [NNT] = 25).

The relative benefit of on-site treatment was greater during the first hours following symptoms onset (Fig. 2). Accordingly, the NNT varied from 10 (45 min after symptoms onset) to 44 (270 min).

The sensitivity analysis showed that within the time range considered, when the penalization of on-site treatment is under 17%, the treatment of choice is on-site thrombolysis.

In the Monte Carlo analysis, biased against on-site treatment through a 30% reduction in effectiveness, on-site therapy was found to be superior to patient referral in 77.2% of the cases.
the local realities and to take all the available resources into account—industriously of the limits imposed by the specialty as such.

Conflict of interest

The authors declare no conflicts of interest.

References